keyword
MENU ▼
Read by QxMD icon Read
search

Fumarate dimethyl

keyword
https://www.readbyqxmd.com/read/27919497/comparative-efficacy-and-discontinuation-of-dimethyl-fumarate-and-fingolimod-in-clinical-practice-at-12-month-follow-up
#1
Carrie M Hersh, Thomas E Love, Samuel Cohn, Claire Hara-Cleaver, Robert A Bermel, Robert J Fox, Jeffrey A Cohen, Daniel Ontaneda
BACKGROUND: Dimethyl fumarate (DMF) and fingolimod (FTY) are approved oral disease modifying therapies (DMT) for relapsing multiple sclerosis (MS). Phase 3 trials established these agents as effective and generally well tolerated, though comparative efficacy and discontinuation remain unknown. OBJECTIVE: To assess real-world efficacy and discontinuation of DMF and FTY over 12 months in patients with MS. METHODS: We identified 458 DMF-treated and 317 FTY-treated patients in a large academic MS center...
November 2016: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/27919491/comparing-outcomes-from-clinical-studies-of-oral-disease-modifying-therapies-dimethyl-fumarate-fingolimod-and-teriflunomide-in-relapsing-ms-assessing-absolute-differences-using-a-number-needed-to-treat-analysis
#2
Mark S Freedman, Xavier Montalban, Aaron E Miller, Catherine Dive-Pouletty, Steven Hass, Karthinathan Thangavelu, Thomas P Leist
Dimethyl fumarate (DMF), fingolimod, and teriflunomide are oral disease-modifying therapies (DMTs) indicated for the treatment of relapsing-remitting multiple sclerosis. Despite well-established limitations of cross-trial comparisons, DMTs are still frequently compared in terms of relative reductions in specific endpoints, most commonly annualized relapse rate. Consideration of absolute risk reduction and number needed to treat (NNT) provides an alternative approach to assess the magnitude of treatment effect and can provide valuable additional information on therapeutic gain...
November 2016: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/27891572/safety-concerns-and-risk-management-of-multiple-sclerosis-therapies
#3
REVIEW
P Soelberg Sorensen
Currently, more than ten drugs have been approved for treatment of relapsing-remitting multiple sclerosis (MS). Newer treatments may be more effective, but have less favorable safety record. Interferon-β preparations and glatiramer acetate treatment require frequent subcutaneous or intramuscular injections and are only moderately effective, but have very rarely life-threatening adverse effects, whereas teriflunomide and dimethyl fumarate are administered orally and have equal or better efficacy, but have more potentially severe adverse effects...
November 27, 2016: Acta Neurologica Scandinavica
https://www.readbyqxmd.com/read/27889959/fumaric-acid-esters-attenuate-secondary-degeneration-following-spinal-cord-injury
#4
Marika Cordaro, Giovanna Casili, Irene Paterniti, Salvatore Cuzzocrea, Emanuela Esposito
Spinal cord injury (SCI) causes permanent changes in motor, sensory and autonomic functions. Unfortunately, there are not a stable cures and current treatments include surgical decompression, methylprednisolone and hemodynamic control that lead to modest function recovery. Fumaric acid esters (FAEs) were firstly used in the management of an immunological skin disorder, such as psoriasis. Because of their potent anti-inflammatory effects, they have been introduced in multiple sclerosis. Investigation shown not only anti-inflammatory, but also supposed neuroprotective mechanism of action...
November 27, 2016: Journal of Neurotrauma
https://www.readbyqxmd.com/read/27888036/desensitization-for-immediate-hypersensitivity-to-oral-dimethyl-fumarate-tecfidera
#5
Danilo Di Bona, Marcello Albanesi, Lucia A Giliberti, Andrea Nico, Maria Pia Rossi, Maria Filomena Caiaffa, Luigi Macchia
No abstract text is available yet for this article.
November 22, 2016: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/27822961/the-cost-effectiveness-of-disease-modifying-therapies-for-the-treatment-of-relapsing-remitting-multiple-sclerosis
#6
Duygu Bozkaya, Terrie Livingston, Kristen Migliaccio-Walle, Tanner Odom
BACKGROUND: The safety and efficacy of disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) has been established; however, it is not clear which provides optimal value, given benefit-risk profiles and costs. AIMS: To compare the cost-effectiveness of current DMTs for patients with RRMS in the US. MATERIALS AND METHODS: A Markov model predicting RRMS course following initiation of a DMT was created comparing outcomes (e...
November 21, 2016: Journal of Medical Economics
https://www.readbyqxmd.com/read/27819376/cascade-oxime-formation-cyclization-to-a-nitrone-and-intermolecular-dipolar-cycloaddition
#7
Rachel C Furnival, Rungroj Saruengkhanphasit, Heather E Holberry, Jonathan R Shewring, Hélène D S Guerrand, Harry Adams, Iain Coldham
Simple haloaldehydes, including enolisable aldehydes, were found to be suitable for the formation of cyclic products by cascade (domino) condensation, cyclisation, dipolar cycloaddition chemistry. This multi-component reaction approach to heterocyclic compounds was explored by using hydroxylamine, a selection of aldehydes, and a selection of activated dipolarophiles. Initial condensation gives intermediate oximes that undergo cyclisation with displacement of halide to give intermediate nitrones; these nitrones undergo in situ intermolecular dipolar cycloaddition reactions to give isoxazolidines...
November 7, 2016: Organic & Biomolecular Chemistry
https://www.readbyqxmd.com/read/27807435/glatiramer-acetate-dimethyl-fumarate-and-monomethyl-fumarate-upregulate-the-expression-of-ccr10-on-the-surface-of-natural-killer-cells-and-enhance-their-chemotaxis-and-cytotoxicity
#8
Azzam A Maghazachi, Kristin L Sand, Zaidoon Al-Jaderi
In vitro harnessing of immune cells is the most important advance in the field of cancer immunotherapy. Results shown in the current paper may be used to harness natural killer (NK) cells in vitro. It is observed that drugs used to treat multiple sclerosis such as glatiramer acetate, dimethyl fumarate, and monomethyl fumarate upregulate the expression of chemokines receptor 10 (CCR10) on the surface of human IL-2-activated NK cells. This is corroborated with increased chemotaxis of these cells toward the concentration gradients of the ligands for CCR10, namely CCL27 and CCL28...
2016: Frontiers in Immunology
https://www.readbyqxmd.com/read/27800021/efficacy-and-tolerability-of-dimethyl-fumarate-in-white-african-and-hispanic-americans-with-multiple-sclerosis
#9
Lana Zhovtis Ryerson, Rivka Green, Gladyne Confident, Krupa Pandey, Benjamin Richter, Tamar Bacon, Carrie Sammarco, Lisa Laing, Jennifer Kalina, Ilya Kister
BACKGROUND: Dimethyl fumarate (DMF) was approved by the US Food and Drug Administration (FDA) for treatment of relapsing-remitting multiple sclerosis (RRMS) based on two phase III randomized clinical trials (RCTs). There were not enough non-White patients enrolled in these RCTs to allow for subgroup analysis based on race. Efficacy and tolerability of DMF therapy across various racial groups is unknown. METHODS: Retrospective chart review was performed on all patients with RRMS who were started on DMF in two tertiary multiple sclerosis (MS) clinics...
November 2016: Therapeutic Advances in Neurological Disorders
https://www.readbyqxmd.com/read/27799046/targeting-the-nrf2-heme-oxygenase-1-axis-after-intracerebral-hemorrhage
#10
Jing Chen-Roetling, Raymond F Regan
BACKGROUND: Injury to cells adjacent to an intracerebral hemorrhage (ICH) is likely mediated at least in part by toxins released from the hematoma that initiate complex and interacting injury cascades. Pharmacotherapies targeting a single toxin or pathway, even if consistently effective in controlled experimental models, have a high likelihood of failure in a variable clinical setting. Nuclear factor erythroid-2 related factor 2 (Nrf2) regulates the expression of heme oxygenase-1 (HO-1) and multiple other proteins with antioxidant and anti-inflammatory effects, and may be a target of interest after ICH...
October 27, 2016: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/27774309/microparticulate-nanoparticulate-powders-of-a-novel-nrf2-activator-and-an-aerosol-performance-enhancer-for-pulmonary-delivery-targeting-the-lung-nrf2-keap-1-pathway
#11
Priya Muralidharan, Don Hayes, Stephen M Black, Heidi M Mansour
This systematic and comprehensive study reports for the first time on the successful rational design of advanced inhalable therapeutic dry powders containing dimethyl fumarate, a first-in-class Nrf2 activator drug to treat pulmonary inflammation, using particle engineering design technology for targeted delivery to the lungs as advanced spray dried (SD) one-component DPIs. In addition, two-component co-spray dried (co-SD) DMF:D-Man DPIs with high drug loading were successfully designed for targeted lung delivery as advanced DPIs using organic solution advanced spray drying in closed mode...
2016: Molecular Systems Design & Engineering
https://www.readbyqxmd.com/read/27744504/the-effect-of-dimethyl-fumarate-on-cerebral-gray-matter-atrophy-in-multiple-sclerosis
#12
Sheena L Dupuy, Shahamat Tauhid, Shelley Hurwitz, Renxin Chu, Fawad Yousuf, Rohit Bakshi
INTRODUCTION: The objective of this pilot study was to compare cerebral gray matter (GM) atrophy over 1 year in patients starting dimethyl fumarate (DMF) for multiple sclerosis (MS) to that of patients on no disease-modifying treatment (noDMT). DMF is an established therapy for relapsing-remitting (RR) MS. METHODS: We retrospectively analyzed 20 patients with RRMS at the start of DMF [age (mean ± SD) 46.1 ± 10.2 years, Expanded Disability Status Scale (EDSS) score 1...
December 2016: Neurology and Therapy
https://www.readbyqxmd.com/read/27739114/commission-regulation-eu-no-412-2012-is-dimethyl-fumarate-still-present-in-products-imported-from-countries-outside-the-european-union
#13
N Milanesi, G Bartolini, S Francalanci, M Gola
Dimethyl fumarate (DMF), the methyl ester form of fumaric acid (DMF) is an effective mold-growth inhibitor. It has a wide-spectrum biocide activity and has been used to protect leather during storage and transport. DMF was first identified as a potent contact sensitizer during a contact dermatitis outbreak that occurred because of its use in Chinese manufactured furniture (1,2). This article is protected by copyright. All rights reserved.
October 14, 2016: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/27733178/fumarate-modulates-the-immune-inflammatory-response-and-rescues-nerve-cells-and-neurological-function-after-stroke-in-rats
#14
Ruihe Lin, Jingli Cai, Eric W Kostuk, Robert Rosenwasser, Lorraine Iacovitti
BACKGROUND: Dimethyl fumarate (DMF), working via its metabolite monomethylfumarate (MMF), acts as a potent antioxidant and immunomodulator in animal models of neurologic disease and in patients with multiple sclerosis. These properties and their translational potential led us to investigate whether DMF/MMF could also protect at-risk and/or dying neurons in models of ischemic stroke in vitro and in vivo. Although the antioxidant effects have been partially addressed, the benefits of DMF immunomodulation after ischemic stroke still need to be explored...
October 13, 2016: Journal of Neuroinflammation
https://www.readbyqxmd.com/read/27733070/comparative-effectiveness-using-a-matching-adjusted-indirect-comparison-between-delayed-release-dimethyl-fumarate-and-fingolimod-for-the-treatment-of-multiple-sclerosis
#15
Robert J Fox, Andrew Chan, Annie Zhang, James Xiao, Dane Levison, James B Lewin, Michael R Edwards, Jing L Marantz
OBJECTIVE: Delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) and fingolimod are approved oral disease-modifying treatments for relapsing-remitting multiple sclerosis. In phase 3 trials, DMF (DEFINE/CONFIRM) and fingolimod (FREEDOMS/FREEDOMS II) resulted in significant reductions in clinical and magnetic resonance imaging activity, with acceptable safety profiles. Direct comparisons of these treatments are not possible due to a lack of head-to-head trials. We compared 2 year efficacy of DMF versus fingolimod at the approved dosage using a matching-adjusted indirect approach...
November 10, 2016: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/27725119/dimethyl-fumarate-alters-microglia-phenotype-and-protects-neurons-against-proinflammatory-toxic-microenvironments
#16
Haiyan Peng, Huo Li, Adam Sheehy, Patrick Cullen, Norm Allaire, Robert H Scannevin
Delayed-release dimethyl fumarate (DMF) is an approved treatment for multiple sclerosis (MS). Microglia are considered central to MS pathophysiology, however the effects of DMF and the primary metabolite monomethyl fumarate (MMF) on microglia are not well characterized. We demonstrated that DMF and MMF altered transcriptional responses in primary microglia related to the nuclear factor (erythroid-derived 2)-like 2 pathway. Additionally, through an NRF2 independent manner, DMF, but not MMF significantly reduced production of proinflammatory mediators in classically activated microglia, and further rescued mitochondrial respiratory deficits in primary cortical neurons that were induced by activated microglia...
October 15, 2016: Journal of Neuroimmunology
https://www.readbyqxmd.com/read/27718209/lipopolysaccharide-binding-protein-and-oxidative-stress-in-a-multiple-sclerosis-model
#17
Begoña M Escribano, Francisco J Medina-Fernández, Macarena Aguilar-Luque, Eduardo Agüera, Montserrat Feijoo, Fe I Garcia-Maceira, Rafael Lillo, Patricia Vieyra-Reyes, Ana I Giraldo, Evelio Luque, René Drucker-Colín, Isaac Túnez
Recent findings in experimental autoimmune encephalomyelitis (EAE) suggest that altering certain bacterial populations present in the gut may lead to a proinflammatory condition, that could result in the development of multiple sclerosis (MS). Also, Reactive Oxygen Species seem to be involved in the course of MS. In this study, it has been aimed to relate all these variables starting from an analysis of the lipopolysaccharide (LPS) and LPS-binding protein (LBP) with the determination of parameters related to oxidative stress in the blood, brain and spinal cord...
October 7, 2016: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://www.readbyqxmd.com/read/27704206/effect-of-teriflunomide-on-quantiferon-tb-gold-results
#18
Alessandra Bua, Melania Ruggeri, Stefania Zanetti, Paola Molicotti
Multiple sclerosis is a chronic inflammatory disease of the central nervous system characterized by damage to myelin and axons, over time leading to progressive neuronal degeneration and microglial activation. There is still no curative treatment, but during the last 20 years eight different therapies have become available including interferon beta, glatiramer acetate, teriflunomide, dimethyl fumarate, natalizumab, fingolimod, alemtuzumab, mitoxantrone and teriflunomide. Teriflunomide is an immunomodulatory drug that exerts an inhibitory effect on T cell activation in central nervous system of the patients with multiple sclerosis...
October 4, 2016: Medical Microbiology and Immunology
https://www.readbyqxmd.com/read/27696299/treatment-related-progressive-multifocal-leukoencephalopathy-in-multiple-sclerosis-a-comprehensive-review-of-current-evidence-and-future-needs
#19
REVIEW
Emanuele D'Amico, Aurora Zanghì, Carmela Leone, Hayrettin Tumani, Francesco Patti
Progressive multifocal leukoencephalopathy (PML) is a rare opportunistic infection of the central nervous system caused by the John Cunningham virus (JCV) that has been associated with therapeutic immunosuppression in patients with multiple sclerosis (MS). So far, more than 600 cases of PML have been reported in association with natalizumab administration. There have also been confirmed cases of PML in individuals who received fingolimod and dimethyl fumarate without previous natalizumab treatment. The new licensed disease-modifying therapies for MS carry the risk of immunosuppressant and so of JCV reactivation...
December 2016: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/27695399/nf-%C3%AE%C2%BAb-pathways-in-the-pathogenesis-of-multiple-sclerosis-and-the-therapeutic-implications
#20
Saskia M Leibowitz, Jun Yan
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathways are involved in cell immune responses, apoptosis and infections. In multiple sclerosis (MS), NF-κB pathways are changed, leading to increased levels of NF-κB activation in cells. This may indicate a key role for NF-κB in MS pathogenesis. NF-κB signaling is complex, with many elements involved in its activation and regulation. Interestingly, current MS treatments are found to be directly or indirectly linked to NF-κB pathways and act to adjust the innate and adaptive immune system in patients...
2016: Frontiers in Molecular Neuroscience
keyword
keyword
27293
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"